New study tracks safety of heart drug mavacamten in pregnancy

NCT ID NCT05939700

Recruiting now Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study is looking at the safety of the heart medication mavacamten when taken during pregnancy or while breastfeeding. Researchers will follow about 20 people who have taken at least one dose of mavacamten during pregnancy or breastfeeding, tracking outcomes for both the mother and baby up to one year after birth. The goal is to better understand any risks or complications, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mavacamten
What this could lead to: If this study succeeds, it could provide important safety information about using mavacamten during pregnancy and breastfeeding, helping doctors and patients make informed decisions.
What could go wrong: This is a small observational study with only 20 participants, so results may not apply to everyone. It is designed to gather data, not to test a new treatment, so no direct health benefits are expected for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREASTFEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Feeding hypertrophic cardiomyopathy pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREASTFEEDING HYPERTROPHIC CARDIOMYOPATHY PREGNANCY RELATED

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

The Mavacamten Pregnancy Surveillance Program, PPD Inc
RECRUITING

Wilmington, North Carolina, 28401-3331, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.